問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

更新時間:2023-09-19

張竣期
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

39Cases

2017-06-26 - 2024-05-31

Phase III

ONO-4538 Phase 3 study A Multicenter, Randomized, Double-Blind Trial in Subjects with Non-Squamous Non-Small Cell Lung Cancer
  • Condition/Disease

    NSCLC

  • Test Drug

    Nivolumab (ONO-4538)

Participate Sites
12Sites

Terminated10Sites

2012-06-01 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
  • Condition/Disease

    TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer

  • Test Drug

    Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

2020-11-01 - 2022-03-11

Phase II

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors
  • Condition/Disease

    Non Small Cell Lung Cancer / Urothelial Cancer / Renal Cell Carcinoma / Hepatocellular Carcinoma / Melanoma

  • Test Drug

    INCB086550

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2020-02-01 - 2023-03-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2008-12-01 - 2010-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-05-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2012-07-01 - 2019-08-31

Phase II/III

A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis
  • Condition/Disease

    A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Test Drug

    Isoniazid tablet formulated with excipient HUEXC030

Participate Sites
13Sites

Terminated13Sites

2012-05-31 - 2018-05-30

Phase III

A Global Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study)
  • Condition/Disease

    Advanced Non-Squamous Non Small Cell Lung Cancer

  • Test Drug

    AMG 706

Participate Sites
9Sites

Study ended9Sites

1 2 3 4